The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2009

Filed:

Oct. 07, 2004
Applicants:

Randolph J. Noelle, Cornish, NH (US);

Fiona H. Durie, Lebanon, NH (US);

David C. Parker, Portland, OR (US);

Michael C. Appel, Golden, CO (US);

Nancy E. Phillips, Shrewsbury, MA (US);

John P. Mordes, Newton, MA (US);

Dale L. Grenier, Hubbardston, MA (US);

Aldo A. Rossini, Sudbury, MA (US);

Inventors:

Randolph J. Noelle, Cornish, NH (US);

Fiona H. Durie, Lebanon, NH (US);

David C. Parker, Portland, OR (US);

Michael C. Appel, Golden, CO (US);

Nancy E. Phillips, Shrewsbury, MA (US);

John P. Mordes, Newton, MA (US);

Dale L. Grenier, Hubbardston, MA (US);

Aldo A. Rossini, Sudbury, MA (US);

Assignees:

Trustees of Dartmouth College, Hanover, NH (US);

University of Massachusetts, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 35/26 (2006.01); A61K 35/28 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
Abstract

Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ. The methods of the invention can be used to induce T cell tolerance to transplants such as liver, kidney, heart, lung, skin, muscle, neuronal tissue, stomach and intestine. A method for treating diabetes comprising administering to a subject allogeneic or xenogeneic cells expressing donor antigens, a gp39 antagonist and pancreatic islets is also disclosed.


Find Patent Forward Citations

Loading…